CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference
CorMedix (Nasdaq: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The event will be held virtually from April 7-10, 2025.
The company's management will engage in a Fireside Chat scheduled for Tuesday, April 8, 2025, at 2:15 p.m. EDT. This participation aligns with CorMedix's ongoing efforts to maintain investor relations and industry presence.
CorMedix (Nasdaq: CRMD), un'azienda biofarmaceutica specializzata in prodotti terapeutici per malattie potenzialmente letali, ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Sanità. L'evento si terrà virtualmente dal 7 al 10 aprile 2025.
La direzione dell'azienda parteciperà a un Fireside Chat programmato per martedì 8 aprile 2025, alle 14:15 EDT. Questa partecipazione è in linea con gli sforzi continui di CorMedix per mantenere le relazioni con gli investitori e la presenza nel settore.
CorMedix (Nasdaq: CRMD), una empresa biofarmacéutica especializada en productos terapéuticos para enfermedades potencialmente mortales, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Needham sobre Salud. El evento se llevará a cabo de manera virtual del 7 al 10 de abril de 2025.
La dirección de la empresa participará en un Fireside Chat programado para el martes 8 de abril de 2025, a las 2:15 p.m. EDT. Esta participación se alinea con los esfuerzos continuos de CorMedix para mantener las relaciones con los inversores y su presencia en la industria.
CorMedix (Nasdaq: CRMD), 생명을 위협하는 질병을 위한 치료 제품을 전문으로 하는 생명공학 회사는 제24회 니드햄 가상 의료 회의에 참여한다고 발표했습니다. 이 행사는 2025년 4월 7일부터 10일까지 가상으로 개최됩니다.
회사의 경영진은 2025년 4월 8일 화요일 오후 2시 15분 EDT에 예정된 파이어사이드 챗에 참여할 것입니다. 이 참여는 CorMedix가 투자자 관계 및 산업 내 존재감을 유지하기 위한 지속적인 노력과 일치합니다.
CorMedix (Nasdaq: CRMD), une entreprise biopharmaceutique spécialisée dans les produits thérapeutiques pour les maladies potentiellement mortelles, a annoncé sa participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé. L'événement se déroulera virtuellement du 7 au 10 avril 2025.
La direction de l'entreprise participera à un Fireside Chat prévu pour le mardi 8 avril 2025, à 14h15 EDT. Cette participation s'inscrit dans les efforts continus de CorMedix pour maintenir ses relations avec les investisseurs et sa présence dans l'industrie.
CorMedix (Nasdaq: CRMD), ein biopharmazeutisches Unternehmen, das sich auf therapeutische Produkte für lebensbedrohliche Krankheiten spezialisiert hat, hat seine Teilnahme an der 24. jährlichen virtuellen Healthcare-Konferenz von Needham bekannt gegeben. Die Veranstaltung findet vom 7. bis 10. April 2025 virtuell statt.
Das Management des Unternehmens wird an einem Fireside Chat teilnehmen, der für Dienstag, den 8. April 2025, um 14:15 Uhr EDT geplant ist. Diese Teilnahme steht im Einklang mit den fortlaufenden Bemühungen von CorMedix, die Beziehungen zu Investoren und die Präsenz in der Branche aufrechtzuerhalten.
- None.
- None.
BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in the 24th Annual Needham Virtual Healthcare Conference, taking place virtually on April 7-10, 2025.
24th Annual Needham Virtual Healthcare Conference
| Date: | Tuesday, April 8, 2025 |
| Time: | 2:15p.m. EDT |
| Format: | Fireside Chat |
| Webcast: | Link |
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When is CorMedix (CRMD) presenting at the Needham Healthcare Conference 2025?
What type of presentation format will CRMD use at the Needham Conference 2025?
What are the dates for the 24th Annual Needham Virtual Healthcare Conference?
What is the main focus of CorMedix (CRMD) as a company?
